Last reviewed · How we verify
MRX-4 co-administered with omeprazole — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
MRX-4 co-administered with omeprazole (MRX-4 co-administered with omeprazole) — MicuRx.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MRX-4 co-administered with omeprazole TARGET | MRX-4 co-administered with omeprazole | MicuRx | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MRX-4 co-administered with omeprazole CI watch — RSS
- MRX-4 co-administered with omeprazole CI watch — Atom
- MRX-4 co-administered with omeprazole CI watch — JSON
- MRX-4 co-administered with omeprazole alone — RSS
Cite this brief
Drug Landscape (2026). MRX-4 co-administered with omeprazole — Competitive Intelligence Brief. https://druglandscape.com/ci/mrx-4-co-administered-with-omeprazole. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab